Basel, Switzerland

Jean-Philippe Carralot

USPTO Granted Patents = 1 

Average Co-Inventor Count = 15.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Jean-Philippe Carralot

Introduction

Jean-Philippe Carralot is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of modified IL-2 polypeptides. His work focuses on innovative treatments for diseases, including cancer.

Latest Patents

Jean-Philippe Carralot holds 1 patent for his invention titled "Modified IL-2 polypeptides and uses thereof." This patent encompasses modified IL-2 polypeptides, compositions that include these polypeptides, methods for their production, and their application in treating various diseases. Notably, the invention highlights the use of modified IL-2 polypeptides for cancer treatment. The disclosed polypeptides demonstrate preferential binding to the IL-2 receptor βγ complex over the IL-2 receptor αβγ complex. Additionally, the molecular weight distribution of these modified polypeptides is characterized as monodispersed.

Career Highlights

Jean-Philippe Carralot is associated with Bright Peak Therapeutics AG, where he continues to advance his research and innovations. His work is pivotal in the ongoing development of therapeutic solutions that leverage the unique properties of modified IL-2 polypeptides.

Collaborations

He collaborates with esteemed colleagues such as Vijaya Raghavan Pattabiraman and Roberto Iacone, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Jean-Philippe Carralot's contributions to biotechnology, particularly through his patented innovations, underscore his role as a leading inventor in the field. His work has the potential to significantly impact cancer treatment and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…